Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer’s Disease and Ischemia-Related Brain Injury

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are oral anti-hyperglycemic agents approved for the treatment of type 2 diabetes mellitus. Some reports suggest their presence in the central nervous system and possible neuroprotective properties. SGLT2 inhibition by empagliflozin has shown to red...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiciński, Michał, Wódkiewicz, Eryk, Górski, Karol, Walczak, Maciej, Malinowski, Bartosz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697611/
https://www.ncbi.nlm.nih.gov/pubmed/33187206
http://dx.doi.org/10.3390/ph13110379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697611/
https://www.ncbi.nlm.nih.gov/pubmed/33187206
http://dx.doi.org/10.3390/ph13110379

Ejemplares similares